Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Threonine SCHEMBL2765872 | 0.93 | SLC7A5 (0.39) | SLC7A5 | |
| SCHEMBL1675353 | 0.85 | SLC7A5 (0.33) | SLC7A5 | |
| SCHEMBL599033 | 0.85 | SLC7A5 (0.41) | SLC7A5 | |
| SCHEMBL28679561 | 0.85 | NAAA (0.33) | SLC7A5 | |
| Leucine SCHEMBL15323191 | 0.84 | SLC7A5 (0.53) | SLC7A5 | |
| Serine SCHEMBL5698241 | 0.84 | SLC7A5 (0.33) | SLC7A5 | |
| Threonine SCHEMBL5073183 | 0.83 | SLC7A5 (0.38) | SLC7A5 | |
| Threonine SCHEMBL6856748 | 0.82 | SLC7A5 (0.36) | SLC7A5 | |
| SCHEMBL1537296 | 0.80 | GRIN2D (0.33) | SLC7A5 | |
| SCHEMBL186138 | 0.80 | GRIN2D (0.33) | SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141786-A2 | MULTITARGET VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | claimed |
| US-5252725-A | α-1-antichymotrypsin, analogues and methods of production | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1993-10-12 | — | — | US | claimed |
| WO-2024141784-A2 | BROADLY PROTECTIVE BETACORONAVIRUS VACCINES AND COMPOSITIONS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141786-A2 | MULTITARGET VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | disclosed |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10202602-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170198287-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-07-13 | — | — | US | disclosed |
| CN-106279715-A | A kind of copper peptide Porous coordination polymer and its preparation method and application | 武汉大学 | 2017-01-04 | — | — | CN | disclosed |
| US-9469664-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2638161-A1 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | Sarepta Therapeutics, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2576574-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | Sarepta Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012064991-A1 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | AVI BIOPHARMA, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122769-A1 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | AVI BIOPHARMA, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2004080920-A1 | HYDROPONIC PLANT NUTRIENT KIT AND METHOD OF USE | ADVANCED NUTRIENTS LTD. (CA) | 2004-09-23 | — | — | WO | disclosed |
| US-20030226753-A1 | Capillaries electrophoresis, chromatography; intersecting channels; switching potentials | RAMSEY J MICHAEL (US) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | SLC7A5 3950/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | SLC7A5 3950/4885 |
| US-20120122769-A1 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | RNGTT, SRRT, RNMT | SLC7A5 335/4885 |
| US-10202602-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | NSUN2, RTCB, UPF1 | SLC7A5 3989/4885 |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | NSUN2, UPF1, RTCB | SLC7A5 3950/4885 |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | SLC7A5 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.